Egetis Therapeutics Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
EGTX
- Investments
-
1
- Share Price
-
$1.12
- (As of Friday Closing)
Egetis Therapeutics General Information
Description
Egetis Therapeutics AB is a Swedish orphan-drug pharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet medical needs. Its product, Emcitate (tiratricol), became the first approved treatment for MCT8 deficiency and was launched in Germany, while FDA approval is being pursued in the U.S.
Contact Information
Website
www.egetis.comCorporate Office
- Klara Norra Kyrkogata 26
- 111 22 Stockholm
- Sweden
Corporate Office
- Klara Norra Kyrkogata 26
- 111 22 Stockholm
- Sweden
Egetis Therapeutics Timeline
Egetis Therapeutics Stock Performance
As of 13-Nov-2026, Egetis Therapeutics’s stock price is $1.12. Its current market cap is $519M with 465M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.12 | $1.12 | $0.38 - $1.14 | $519M | 465M | 2.56M | -$0.12 |
Egetis Therapeutics Financials Summary
As of 30-Sep-2026, Egetis Therapeutics has a trailing 12-month revenue of $7.47M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 380,719 | 223,187 | 226,776 | 154,849 |
| Revenue | 7,471 | 6,351 | 4,359 | 5,419 |
| EBITDA | (49,732) | (33,507) | (31,108) | (30,473) |
| Net Income | (50,030) | (34,861) | (32,489) | (30,755) |
| Total Assets | 65,515 | 69,453 | 71,809 | 76,066 |
| Total Debt | 7,043 | 9,846 | 10,640 | 11,307 |
Egetis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Egetis Therapeutics Comparisons
Industry
Financing
Details
Egetis Therapeutics Competitors (1)
One of Egetis Therapeutics’s competitors is AviadoBio, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AviadoBio | Venture Capital-Backed | London, United Kingdom |
Egetis Therapeutics Patents
Egetis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022019973-A | Methods and formulations for treating and / or protecting acute liver failure and other hepatotoxic conditions | Active | 11-Jan-2016 | ||
| AU-2017208123-A1 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | Active | 11-Jan-2016 | ||
| AU-2017208123-B2 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | Active | 11-Jan-2016 | ||
| CA-3010915-A1 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | Active | 11-Jan-2016 | ||
| CA-3010915-C | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | Active | 11-Jan-2016 | A61K31/555 |
Egetis Therapeutics Signals
Egetis Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Egetis Therapeutics Acquisitions (1)
Egetis Therapeutics’s most recent deal was a Merger/Acquisition with Rare Thyroid Therapeutics for . The deal was made on 03-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rare Thyroid Therapeutics | 03-Nov-2020 | Merger/Acquisition | Drug Discovery |
Egetis Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Egetis Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Rare Thyroid Therapeutics | Stockholm, Sweden | 2013 | |
| Egetis Therapeutics Incentive | Stockholm, Sweden | 2012 |
Egetis Therapeutics FAQs
-
When was Egetis Therapeutics founded?
Egetis Therapeutics was founded in 2006.
-
Where is Egetis Therapeutics headquartered?
Egetis Therapeutics is headquartered in Stockholm, Sweden.
-
What is the size of Egetis Therapeutics?
Egetis Therapeutics has 44 total employees.
-
What industry is Egetis Therapeutics in?
Egetis Therapeutics’s primary industry is Pharmaceuticals.
-
Is Egetis Therapeutics a private or public company?
Egetis Therapeutics is a Public company.
-
What is Egetis Therapeutics’s stock symbol?
The ticker symbol for Egetis Therapeutics is EGTX.
-
What is the current stock price of Egetis Therapeutics?
As of 13-Nov-2026 the stock price of Egetis Therapeutics is $1.12.
-
What is the current market cap of Egetis Therapeutics?
The current market capitalization of Egetis Therapeutics is $519M.
-
What is Egetis Therapeutics’s current revenue?
The trailing twelve month revenue for Egetis Therapeutics is $7.47M.
-
Who are Egetis Therapeutics’s competitors?
AviadoBio is a competitor of Egetis Therapeutics.
-
What is Egetis Therapeutics’s annual earnings per share (EPS)?
Egetis Therapeutics’s EPS for 12 months was -$0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process